Results for Cellular Toxicity

1 - 10 of 27

Dr. Myers aims to improve outcomes for children and young adults receiving cellular immunotherapies for high-risk hematologic toxicities. Her current research is focused on studying toxicities of CAR T-cell therapies through a combination of clinical epidemiologic and translational research methods.

E-mail:

myersrm [at] chop.edu

Ophir Shalem, PhD

Dr. Shalem’s research focuses on translational target discovery for a range of neurodegenerative diseases. He combines technology development of large-scale CRISPR-based perturbation screens with application of such technology together with additional genomic approaches.

E-mail:

shalemo [at] chop.edu

Where Discovery Leads: Taking CAR T-Cell Therapy to Solid Tumors and Beyond

Published on

Sep 19, 2022

in Cornerstone Blog

Where Discovery Leads: CAR T-Cell Therapy Research

CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

CHOP Researchers Join Global Team to Take On Solid Cancers

Published on

Jun 29, 2022

in Cornerstone Blog

CHOP Researchers Join Global Team to Take On Solid Cancers

CHOP scientists are part of a Cancer Grand Challenges team receiving $25 million to tackle solid tumors.

Emily Whitehead, 10 Years Later: Q&A With Stephan Grupp, MD, PhD

Published on

May 11, 2022

in Cornerstone Blog

Emily Whitehead, 10 Years Later: Q&A With Stephan Grupp, MD, PhD

In this Q&A, Stephan Grupp, MD, PhD, discusses his experience delivering CAR T-cell therapy to the first pediatric patient, Emily Whitehead.

In The News: STAT Madness, Autistic Adolescents, Invasive Candidiasis, Allergen Label Warnings, ASH 2022 Scholar Awards

Published on

Mar 4, 2022

in Cornerstone Blog

Our Scientists’ Research Highlighted In the News

Learn about novel findings and new funding from our Children’s Hospital of Philadelphia researchers.

Snapshot Science: How Did Researchers Resolve Adverse Symptoms that Emerged with AAV-based RNA Interference Strategies for Ataxia Therapy?

Published on

Oct 18, 2021

in Cornerstone Blog

Researchers Resolve Symptoms that Emerged with AAV-based RNAi for SCA1

Raymond G. Perelman Center for Cellular and Molecular Therapeutics team highlights that extended safety testing of AAV-based RNAi strategies is critical.